What is the appropriate oral tablet regimen for treating uncomplicated typhoid fever caused by Salmonella Typhi?

Oral Tablet Treatment for Typhoid Fever (S. Typhi)

For uncomplicated typhoid fever caused by Salmonella Typhi, azithromycin 20 mg/kg/day orally for 7 days is the preferred first-line oral tablet regimen, particularly in regions with high rates of fluoroquinolone resistance. 1

Treatment Algorithm Based on Resistance Patterns

First-Line Therapy: Azithromycin

• Dosing: 20 mg/kg/day orally for 7 days (maximum 500 mg/day in children)
• Rationale: Azithromycin demonstrates superior outcomes compared to fluoroquinolones, with:
  • Lower clinical failure rates (OR 0.48; 95% CI 0.26-0.89)
  • Shorter hospital stays (-1.04 days)
  • Significantly lower relapse rates compared to ceftriaxone (OR 0.09; 95% CI 0.01-0.70) 1
• Clinical cure rate: 85% with mean fever clearance time of 5.8 days 2

Alternative Oral Options (When Azithromycin Unavailable or Contraindicated)

For Fully Susceptible Strains:

• Fluoroquinolones remain an option per WHO guidelines 1:
  • Ciprofloxacin: 20 mg/kg/day for 14 days
  • Ofloxacin: 15 mg/kg/day for 2-3 days (adults only)
  • Gatifloxacin: 10 mg/kg/day for 7 days

For Multidrug-Resistant (MDR) Strains:

• Cefixime: 16 mg/kg/day for 14 days (clinical cure rate 71%, fever clearance 7.1 days) 2
• Azithromycin remains preferred 1

For Quinolone-Resistant Strains:

• Azithromycin is the oral agent of choice 1
• Cefixime as alternative 1

Critical Resistance Considerations

The fluoroquinolone landscape has dramatically changed:

• 93.5% of S. Typhi isolates in recent studies show nalidixic acid resistance (NAR) 2
• 88.7% demonstrate multidrug resistance 2
• Treatment failures with fluoroquinolones are significantly higher with NAR strains (relative risk 13.5) 3
• Ciprofloxacin shows only 62% clinical cure rate in current MDR/NAR contexts 2

Common Pitfall: The WHO 2012 guidelines 1 list fluoroquinolones as first-line, but this recommendation predates the widespread emergence of quinolone resistance. The 2008 systematic review data 1 showing azithromycin superiority, combined with 2021 clinical trial evidence 2 demonstrating poor fluoroquinolone performance in contemporary resistance patterns, makes azithromycin the evidence-based choice for empiric therapy.

Practical Implementation

When to use each regimen:

1. Unknown susceptibility (empiric therapy): Start azithromycin 20 mg/kg/day × 7 days
2. Culture confirms full susceptibility: May continue azithromycin or switch to shorter fluoroquinolone course if cost is prohibitive
3. Known quinolone resistance: Azithromycin mandatory; cefixime if azithromycin unavailable
4. Treatment failure at 5-7 days: Switch to parenteral ceftriaxone

Monitoring: Expect fever clearance within 5-8 days with azithromycin. Failure to defervesce by day 7 warrants reassessment and consideration of complications or resistance.

Cost-Effectiveness Note

While gatifloxacin costs approximately one-third that of azithromycin 4, the superior efficacy and lower relapse rates of azithromycin justify its use as first-line therapy, particularly given the high prevalence of fluoroquinolone resistance globally. The reduced hospitalization time with azithromycin (-1.04 days) 1 offsets medication cost differences.